Relationship Between Cetuximab Target-Mediated Pharmacokinetics and Progression-Free Survival in Metastatic Colorectal Cancer Patients.

Sarah LobetGilles PaintaudNicolas AzzopardiChristophe PassotMorgane CauletRomain ChautardCéline DesvignesOlivier CapitainDavid TougeronThierry LecomteDavid Ternant

Published in: Clinical pharmacokinetics (2023)

This is the first study describing the complex relationship between cetuximab target-mediated pharmacokinetics and PFS in mCRC patients using a joint PK-time-to-progression model. Further studies are needed to provide a more in-depth description of this relationship.

Keyphrases

metastatic colorectal cancer
end stage renal disease
newly diagnosed
chronic kidney disease
free survival
prognostic factors
radiation therapy
locally advanced